Exisulind Versus Placebo After Surgical Removal of the Prostate
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This is a study in which patients with prostate cancer treated by surgical removal of the
prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind
250 mg twice a day or placebo twice a day for two years.